Business Description
Epigenomics AG
ISIN : DE000A37FT41
Total Employee Number:
3Description
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.04 | |||||
Debt-to-Equity | 5690.5 | |||||
Debt-to-EBITDA | -36.25 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -9.4 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -70.9 | |||||
3-Year EBITDA Growth Rate | 69.4 | |||||
3-Year EPS without NRI Growth Rate | 73.4 | |||||
3-Year FCF Growth Rate | 64.1 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.57 | |||||
9-Day RSI | 45.51 | |||||
14-Day RSI | 45.98 | |||||
3-1 Month Momentum % | 1.15 | |||||
6-1 Month Momentum % | -2.22 | |||||
12-1 Month Momentum % | 37.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 110.25 | |||||
Quick Ratio | 110.25 | |||||
Cash Ratio | 103.5 | |||||
Days Sales Outstanding | 136.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | 2.62 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1387.5 | |||||
Net Margin % | -1308.33 | |||||
EBITDA Margin % | -1308.33 | |||||
FCF Margin % | -2220.83 | |||||
OCF Margin % | -2220.83 | |||||
ROE % | -47100 | |||||
ROA % | -2.67 | |||||
ROIC % | -3.01 | |||||
3-Year ROIIC % | 287.6 | |||||
ROC (Joel Greenblatt) % | -1184.91 | |||||
ROCE % | -2.67 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 31.07 | |||||
PB Ratio | 435 | |||||
EV-to-EBIT | -37.36 | |||||
EV-to-EBITDA | -37.36 | |||||
EV-to-Forward-EBITDA | 27.99 | |||||
EV-to-Revenue | 488.75 | |||||
EV-to-Forward-Revenue | 9.44 | |||||
EV-to-FCF | -22.01 | |||||
Price-to-GF-Value | 9.67 | |||||
Earnings Yield (Greenblatt) % | -2.68 | |||||
FCF Yield % | -69.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Epigenomics AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.024 | ||
| EPS (TTM) (€) | -0.358 | ||
| Beta | 0.3582 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.12 | ||
| Volatility % | 64.82 | ||
| 14-Day RSI | 45.98 | ||
| 14-Day ATR (€) | 0.017797 | ||
| 20-Day SMA (€) | 0.8775 | ||
| 12-1 Month Momentum % | 37.5 | ||
| 52-Week Range (€) | 0.51 - 1.59 | ||
| Shares Outstanding (Mil) | 0.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Epigenomics AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Epigenomics AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-08-27 10:30 | In 57 days | ||
| Second quarter earnings results for 2026 | 2026-07-22 | In 20 days | ||
| Annual report for 2025 | 2026-04-01 | 0.87 (+0.00%) | ||
| General meeting for 2025 | 2025-08-27 10:30 | 1.20 (+37.93%) | ||
| Second quarter earnings results for 2025 | 2025-07-22 | 0.86 (+0.00%) | ||
| Annual report for 2024 | 2025-04-25 | 0.88 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-09-30 | 0.59 (-7.81%) | ||
| 0.2:1 Stock Split | 2023-12-08 | 2.50 (+0.00%) | ||
| 0.25:1 Stock Split | 2022-12-27 | 7.00 (+0.00%) | ||
| 0.125:1 Stock Split | 2020-12-11 | 70.93 (+2.27%) |
Show
Entries
Epigenomics AG Frequently Asked Questions
What is Epigenomics AG(FRA:ECX)'s stock price today?
The current price of FRA:ECX is €0.87. The 52 week high of FRA:ECX is €1.59 and 52 week low is €0.51.
When is next earnings date of Epigenomics AG(FRA:ECX)?
The next earnings date of Epigenomics AG(FRA:ECX) is 2026-07-22 Est..
Does Epigenomics AG(FRA:ECX) pay dividends? If so, how much?
Epigenomics AG(FRA:ECX) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Encode Ideas, L.P. to host Virtual 1x1 Webinar with Epigenomics AG (ECX.DE, EPGNF) on Tuesday, July 28th at 10:30 AM ET | 2020-07-23 |
Articles on Epigenomics AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers